The FDA will likely fast-track the authorization in less than two months, according to Scott Gottlieb, who served as FDA Commissioner from May 2017 to April 2019 and then jumped to Pfizer’s corporate board in June 2019.
The elderly and obese have been vaccinated, as should have happened. Healthy adults were forced to vaccinate to keep their jobs.
— Cernovich (@Cernovich) October 7, 2021
“FDA has said the review is going to be a matter of weeks, not months,” Gottlieb said on Face the Nation.
“I interpret that to mean potentially a four-week review, maybe a six-week review,” he continued. “So, I think on the low end it could take four weeks and that could give you a vaccine by Halloween.”
The Pfizer shot for young children reportedly contains one-third of the active ingredient that adults receive in the two-dose formula.
Pfizer studied only 2,268 children aged 5 to 11 for a vaccine that could effect millions of children. The study did not record any side effects.
“Our study confirms that vaccines are a critical tool for controlling the pandemic and remain highly effective in preventing severe disease and hospitalization, including from the Delta and other variants of concern,” the study’s lead author, Dr. Sara Tartof, said in a statement, according to HealthDay News.
“Protection against infection does decline in the months following a second dose,” Tartof added.
COVID-19 vaccines have caused heart defects and myocarditis in much higher than expected levels, especially in young men.
Sweden suspended the Moderna shot for people younger than 30 due to the risk of heart defects.
Pfizer noted that, in a study of 3.5 million people, the COVID shots offered 90% protection against serious illness for the first six months after taking them.
Most of the healthy population will not face serious illness from COVID-19 anyway but will instead feel symptoms ranging from a mild cold to the flu.